Survival Outcomes of Calcium Channel Blocker Therapy in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Inhibitors: A Retrospective Study

被引：2
作者：
Hsieh, Hui-Hsia [1 ,2 ]
Wu, Tien-Yuan [1 ,3 ]
Chen, Chi-Hua [1 ]
Kuo, Yu-Hung [4 ]
Hour, Mann-Jen [2 ,5 ]
机构：
[1] Taichung Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Pharm, Taichung, Taiwan
[2] China Med Univ, Sch Pharm, Taichung, Taiwan
[3] Tzu Chi Univ, Grad Inst Clin Pharm, Hualien, Taiwan
[4] Taichung Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Res, Taichung, Taiwan
[5] China Med Univ, Sch Pharm, 100,Sec 1,Jingmao Rd, Taichung 406040, Taiwan
来源：
INTEGRATIVE CANCER THERAPIES | 2023年 / 22卷
关键词：
epidermal growth factor receptor tyrosine kinase inhibitors; calcium channel blockers; non-small cell lung cancer; targeted therapy; cancer therapy; CLINICAL IMPACT; ERLOTINIB; NSCLC;
D O I：
10.1177/15347354231178903
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background:Non-cancer drugs are currently being repurposed for cancer treatment. Mounting evidence highlights the influence of calcium channels on tumorigenesis and progression. Hence, inhibition of calcium signaling may be a promising cancer treatment strategy. Objective:In this study, we aimed to examine whether calcium channel blockers (CCBs) affect the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung cancer (NSCLC). Design:We conducted a retrospective analysis. Methods:In this study, conducted between January 2009 and June 2021, patients with NSCLC treated with erlotinib, or gefitinib for at least 1 week were enrolled and divided into 2 groups: CCBs-/EGFR-TKIs+ and CCBs+/EGFR-TKIs+, depending on whether they received CCB therapy. Progression-free survival (PFS) and overall survival (OS) were determined as the primary and secondary endpoints, respectively. Results: The estimated median PFS and OS for the CCBs-/EGFR-TKIs+group were 7.70 and 12.17 months, respectively, and they were significantly different from those of the CCBs+/EGFR-TKIs+ group (10.43 and 18.07 months, respectively). CCB use was associated with improved PFS (adjusted hazard ratios [HR] 0.77, 95% confidence interval [CI]: 0.61-0.98; P = .035) and OS (adjusted HR 0.66, 95% CI: 0.51-0.84; P < .001). Conclusion:Calcium channels have been implicated in cancer pathogenesis. Our findings revealed the potential additive anticancer effects of CCBs when used concomitantly with EGFR-TKIs. However, study limitations, including the retrospective nature and small number of patients, necessitate large-scale prospective studies on the therapeutic potential of CCB as an adjunctive therapy with EGFR-TKIs in patients with NSCLC.
引用
收藏
页数：9
相关论文
共 50 条
[21]   Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wildtype non-small cell lung cancer? [J].
Arriola, Edurne ;
Taus, Alvaro ;
Casadevall, David .
WORLD JOURNAL OF CLINICAL ONCOLOGY, 2015, 6 (04) :45-56
[22]   Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery [J].
Yang, Wen-Chi ;
Xiao, Furen ;
Shih, Jin-Yuan ;
Ho, Chao-Chi ;
Chen, Ya-Fang ;
Tseng, Ham-Min ;
Chen, Kuan-Yu ;
Liao, Wei-Yu ;
Yu, Chong-Jen ;
Yang, James Chih-Hsin ;
Kuo, Sung-Hsin ;
Cheng, Jason Chia-Hsien ;
Yang, Pan-Chyr ;
Hsu, Feng-Ming .
RADIOTHERAPY AND ONCOLOGY, 2018, 126 (02) :368-374
[23]   Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer [J].
Kujtan, Lara ;
Subramanian, Janakiraman .
EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (07) :547-559
[24]   Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer [J].
周清 ;
魏雪武 ;
高欣 ;
何韵婷 ;
杨潇蓉 .
ScienceFoundationinChina, 2019, 27 (01) :72-80
[25]   Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer [J].
Ogunleye, Foluso ;
Ibrahim, Mohammed ;
Stender, Michael ;
Kalemkerian, Gregory ;
Jaiyesimi, Ishmael .
AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (01) :16-25
[26]   Targeted Therapy for the Treatment of Non-Small Cell Lung Cancer: Focus on Inhibition of Epidermal Growth Factor Receptor [J].
Harichand-Herdt, Seema ;
Ramalingam, Suresh S. .
SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2008, 20 (03) :217-223
[27]   Feasibility of Rebiopsy in Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors [J].
Hasegawa, Takaaki ;
Sawa, Toshiyuki ;
Futamura, Yohei ;
Horiba, Akane ;
Ishiguro, Takashi ;
Marui, Tsutomu ;
Yoshida, Tsutomu .
INTERNAL MEDICINE, 2015, 54 (16) :1977-1980
[28]   Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study [J].
Gijtenbeek, Rolof G. P. ;
Damhuis, Ronald A. M. ;
Wekken, Anthonie J. van der ;
Hendriks, Lizza E. L. ;
Groen, Harry J. M. ;
Geffen, Wouter H. van .
LANCET REGIONAL HEALTH-EUROPE, 2023, 27
[29]   Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors [J].
Jumpei Kashima ;
Yusuke Okuma ;
Maki Miwa ;
Yukio Hosomi .
Medical Oncology, 2016, 33
[30]   Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis [J].
Hakozaki, Taiki ;
Okuma, Yusuke ;
Hashimoto, Kana ;
Hosomi, Yukio .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (10) :2555-2564
12345